Global Dendritic Cell Cancer Vaccine Market Research Report 2023

Publisher Name :
Date: 07-Feb-2023
No. of pages: 109
Inquire Before Buying

Dendritic cells (DCs) refer to rare kind of leukocytes. They have prompted their recent application to therapeutic cancer vaccinations as they are uniquely effective in their ability to present antigens to T cells.

Highlights

The global Dendritic Cell Cancer Vaccine market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.

North American market for Dendritic Cell Cancer Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Dendritic Cell Cancer Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global manufacturers of Dendritic Cell Cancer Vaccine include Activarti, Argos Therapeutics, SOTIO (Acquired by PPF Group), Bellicum Pharmaceuticals, JW CreaGene, DanDrit, DCPrime, Elios Therapeutics and ImmunoCellular Therapeutics, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Dendritic Cell Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dendritic Cell Cancer Vaccine.

The Dendritic Cell Cancer Vaccine market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Dendritic Cell Cancer Vaccine market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Dendritic Cell Cancer Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.

By Company

- Activarti

- Argos Therapeutics

- SOTIO (Acquired by PPF Group)

- Bellicum Pharmaceuticals

- JW CreaGene

- DanDrit

- DCPrime

- Elios Therapeutics

- ImmunoCellular Therapeutics

- Kiromic

- Medigene

- Merck

- Northwest Biotherapeutics

- Immutep Limited

- Dendreon Corporation

- Oncobiomed

Segment by Type

- CreaVax

- Sipuleucel-T (Provenge)

- Others

Segment by Application

- Pediatrics

- Adults

Consumption by Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - U.A.E

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Detailed analysis of Dendritic Cell Cancer Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Sales, revenue of Dendritic Cell Cancer Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 9: The main points and conclusions of the report.

Global Dendritic Cell Cancer Vaccine Market Research Report 2023

Table of Contents
1 Dendritic Cell Cancer Vaccine Market Overview
1.1 Product Overview and Scope of Dendritic Cell Cancer Vaccine
1.2 Dendritic Cell Cancer Vaccine Segment by Type
1.2.1 Global Dendritic Cell Cancer Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 CreaVax
1.2.3 Sipuleucel-T (Provenge)
1.2.4 Others
1.3 Dendritic Cell Cancer Vaccine Segment by Application
1.3.1 Global Dendritic Cell Cancer Vaccine Market Value by Application: (2023-2029)
1.3.2 Pediatrics
1.3.3 Adults
1.4 Global Dendritic Cell Cancer Vaccine Market Size Estimates and Forecasts
1.4.1 Global Dendritic Cell Cancer Vaccine Revenue 2018-2029
1.4.2 Global Dendritic Cell Cancer Vaccine Sales 2018-2029
1.4.3 Global Dendritic Cell Cancer Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Dendritic Cell Cancer Vaccine Market Competition by Manufacturers
2.1 Global Dendritic Cell Cancer Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Dendritic Cell Cancer Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Dendritic Cell Cancer Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Dendritic Cell Cancer Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Dendritic Cell Cancer Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Dendritic Cell Cancer Vaccine, Product Type & Application
2.7 Dendritic Cell Cancer Vaccine Market Competitive Situation and Trends
2.7.1 Dendritic Cell Cancer Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Dendritic Cell Cancer Vaccine Players Market Share by Revenue
2.7.3 Global Dendritic Cell Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Dendritic Cell Cancer Vaccine Retrospective Market Scenario by Region
3.1 Global Dendritic Cell Cancer Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Dendritic Cell Cancer Vaccine Global Dendritic Cell Cancer Vaccine Sales by Region: 2018-2029
3.2.1 Global Dendritic Cell Cancer Vaccine Sales by Region: 2018-2023
3.2.2 Global Dendritic Cell Cancer Vaccine Sales by Region: 2024-2029
3.3 Global Dendritic Cell Cancer Vaccine Global Dendritic Cell Cancer Vaccine Revenue by Region: 2018-2029
3.3.1 Global Dendritic Cell Cancer Vaccine Revenue by Region: 2018-2023
3.3.2 Global Dendritic Cell Cancer Vaccine Revenue by Region: 2024-2029
3.4 North America Dendritic Cell Cancer Vaccine Market Facts & Figures by Country
3.4.1 North America Dendritic Cell Cancer Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Dendritic Cell Cancer Vaccine Sales by Country (2018-2029)
3.4.3 North America Dendritic Cell Cancer Vaccine Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Dendritic Cell Cancer Vaccine Market Facts & Figures by Country
3.5.1 Europe Dendritic Cell Cancer Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Dendritic Cell Cancer Vaccine Sales by Country (2018-2029)
3.5.3 Europe Dendritic Cell Cancer Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Dendritic Cell Cancer Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Dendritic Cell Cancer Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Dendritic Cell Cancer Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Dendritic Cell Cancer Vaccine Market Facts & Figures by Country
3.7.1 Latin America Dendritic Cell Cancer Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Dendritic Cell Cancer Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Dendritic Cell Cancer Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Dendritic Cell Cancer Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Dendritic Cell Cancer Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Dendritic Cell Cancer Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Dendritic Cell Cancer Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Dendritic Cell Cancer Vaccine Sales by Type (2018-2029)
4.1.1 Global Dendritic Cell Cancer Vaccine Sales by Type (2018-2023)
4.1.2 Global Dendritic Cell Cancer Vaccine Sales by Type (2024-2029)
4.1.3 Global Dendritic Cell Cancer Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Dendritic Cell Cancer Vaccine Revenue by Type (2018-2029)
4.2.1 Global Dendritic Cell Cancer Vaccine Revenue by Type (2018-2023)
4.2.2 Global Dendritic Cell Cancer Vaccine Revenue by Type (2024-2029)
4.2.3 Global Dendritic Cell Cancer Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Dendritic Cell Cancer Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Dendritic Cell Cancer Vaccine Sales by Application (2018-2029)
5.1.1 Global Dendritic Cell Cancer Vaccine Sales by Application (2018-2023)
5.1.2 Global Dendritic Cell Cancer Vaccine Sales by Application (2024-2029)
5.1.3 Global Dendritic Cell Cancer Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Dendritic Cell Cancer Vaccine Revenue by Application (2018-2029)
5.2.1 Global Dendritic Cell Cancer Vaccine Revenue by Application (2018-2023)
5.2.2 Global Dendritic Cell Cancer Vaccine Revenue by Application (2024-2029)
5.2.3 Global Dendritic Cell Cancer Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Dendritic Cell Cancer Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Activarti
6.1.1 Activarti Corporation Information
6.1.2 Activarti Description and Business Overview
6.1.3 Activarti Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Activarti Dendritic Cell Cancer Vaccine Product Portfolio
6.1.5 Activarti Recent Developments/Updates
6.2 Argos Therapeutics
6.2.1 Argos Therapeutics Corporation Information
6.2.2 Argos Therapeutics Description and Business Overview
6.2.3 Argos Therapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Argos Therapeutics Dendritic Cell Cancer Vaccine Product Portfolio
6.2.5 Argos Therapeutics Recent Developments/Updates
6.3 SOTIO (Acquired by PPF Group)
6.3.1 SOTIO (Acquired by PPF Group) Corporation Information
6.3.2 SOTIO (Acquired by PPF Group) Description and Business Overview
6.3.3 SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Product Portfolio
6.3.5 SOTIO (Acquired by PPF Group) Recent Developments/Updates
6.4 Bellicum Pharmaceuticals
6.4.1 Bellicum Pharmaceuticals Corporation Information
6.4.2 Bellicum Pharmaceuticals Description and Business Overview
6.4.3 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Product Portfolio
6.4.5 Bellicum Pharmaceuticals Recent Developments/Updates
6.5 JW CreaGene
6.5.1 JW CreaGene Corporation Information
6.5.2 JW CreaGene Description and Business Overview
6.5.3 JW CreaGene Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 JW CreaGene Dendritic Cell Cancer Vaccine Product Portfolio
6.5.5 JW CreaGene Recent Developments/Updates
6.6 DanDrit
6.6.1 DanDrit Corporation Information
6.6.2 DanDrit Description and Business Overview
6.6.3 DanDrit Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 DanDrit Dendritic Cell Cancer Vaccine Product Portfolio
6.6.5 DanDrit Recent Developments/Updates
6.7 DCPrime
6.6.1 DCPrime Corporation Information
6.6.2 DCPrime Description and Business Overview
6.6.3 DCPrime Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 DCPrime Dendritic Cell Cancer Vaccine Product Portfolio
6.7.5 DCPrime Recent Developments/Updates
6.8 Elios Therapeutics
6.8.1 Elios Therapeutics Corporation Information
6.8.2 Elios Therapeutics Description and Business Overview
6.8.3 Elios Therapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Elios Therapeutics Dendritic Cell Cancer Vaccine Product Portfolio
6.8.5 Elios Therapeutics Recent Developments/Updates
6.9 ImmunoCellular Therapeutics
6.9.1 ImmunoCellular Therapeutics Corporation Information
6.9.2 ImmunoCellular Therapeutics Description and Business Overview
6.9.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.9.4 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Product Portfolio
6.9.5 ImmunoCellular Therapeutics Recent Developments/Updates
6.10 Kiromic
6.10.1 Kiromic Corporation Information
6.10.2 Kiromic Description and Business Overview
6.10.3 Kiromic Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Kiromic Dendritic Cell Cancer Vaccine Product Portfolio
6.10.5 Kiromic Recent Developments/Updates
6.11 Medigene
6.11.1 Medigene Corporation Information
6.11.2 Medigene Dendritic Cell Cancer Vaccine Description and Business Overview
6.11.3 Medigene Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Medigene Dendritic Cell Cancer Vaccine Product Portfolio
6.11.5 Medigene Recent Developments/Updates
6.12 Merck
6.12.1 Merck Corporation Information
6.12.2 Merck Dendritic Cell Cancer Vaccine Description and Business Overview
6.12.3 Merck Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Merck Dendritic Cell Cancer Vaccine Product Portfolio
6.12.5 Merck Recent Developments/Updates
6.13 Northwest Biotherapeutics
6.13.1 Northwest Biotherapeutics Corporation Information
6.13.2 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Description and Business Overview
6.13.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Product Portfolio
6.13.5 Northwest Biotherapeutics Recent Developments/Updates
6.14 Immutep Limited
6.14.1 Immutep Limited Corporation Information
6.14.2 Immutep Limited Dendritic Cell Cancer Vaccine Description and Business Overview
6.14.3 Immutep Limited Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Immutep Limited Dendritic Cell Cancer Vaccine Product Portfolio
6.14.5 Immutep Limited Recent Developments/Updates
6.15 Dendreon Corporation
6.15.1 Dendreon Corporation Corporation Information
6.15.2 Dendreon Corporation Dendritic Cell Cancer Vaccine Description and Business Overview
6.15.3 Dendreon Corporation Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Dendreon Corporation Dendritic Cell Cancer Vaccine Product Portfolio
6.15.5 Dendreon Corporation Recent Developments/Updates
6.16 Oncobiomed
6.16.1 Oncobiomed Corporation Information
6.16.2 Oncobiomed Dendritic Cell Cancer Vaccine Description and Business Overview
6.16.3 Oncobiomed Dendritic Cell Cancer Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Oncobiomed Dendritic Cell Cancer Vaccine Product Portfolio
6.16.5 Oncobiomed Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Dendritic Cell Cancer Vaccine Industry Chain Analysis
7.2 Dendritic Cell Cancer Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Dendritic Cell Cancer Vaccine Production Mode & Process
7.4 Dendritic Cell Cancer Vaccine Sales and Marketing
7.4.1 Dendritic Cell Cancer Vaccine Sales Channels
7.4.2 Dendritic Cell Cancer Vaccine Distributors
7.5 Dendritic Cell Cancer Vaccine Customers
8 Dendritic Cell Cancer Vaccine Market Dynamics
8.1 Dendritic Cell Cancer Vaccine Industry Trends
8.2 Dendritic Cell Cancer Vaccine Market Drivers
8.3 Dendritic Cell Cancer Vaccine Market Challenges
8.4 Dendritic Cell Cancer Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Dendritic Cell Cancer Vaccine Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Dendritic Cell Cancer Vaccine Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Dendritic Cell Cancer Vaccine Market Competitive Situation by Manufacturers in 2022
Table 4. Global Dendritic Cell Cancer Vaccine Sales (Units) of Key Manufacturers (2018-2023)
Table 5. Global Dendritic Cell Cancer Vaccine Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Dendritic Cell Cancer Vaccine Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Dendritic Cell Cancer Vaccine Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Dendritic Cell Cancer Vaccine Average Price (USD/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Dendritic Cell Cancer Vaccine, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Dendritic Cell Cancer Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Dendritic Cell Cancer Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Dendritic Cell Cancer Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Dendritic Cell Cancer Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccine as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Dendritic Cell Cancer Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Dendritic Cell Cancer Vaccine Sales by Region (2018-2023) & (Units)
Table 18. Global Dendritic Cell Cancer Vaccine Sales Market Share by Region (2018-2023)
Table 19. Global Dendritic Cell Cancer Vaccine Sales by Region (2024-2029) & (Units)
Table 20. Global Dendritic Cell Cancer Vaccine Sales Market Share by Region (2024-2029)
Table 21. Global Dendritic Cell Cancer Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Region (2018-2023)
Table 23. Global Dendritic Cell Cancer Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Region (2024-2029)
Table 25. North America Dendritic Cell Cancer Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Dendritic Cell Cancer Vaccine Sales by Country (2018-2023) & (Units)
Table 27. North America Dendritic Cell Cancer Vaccine Sales by Country (2024-2029) & (Units)
Table 28. North America Dendritic Cell Cancer Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Dendritic Cell Cancer Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Dendritic Cell Cancer Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Dendritic Cell Cancer Vaccine Sales by Country (2018-2023) & (Units)
Table 32. Europe Dendritic Cell Cancer Vaccine Sales by Country (2024-2029) & (Units)
Table 33. Europe Dendritic Cell Cancer Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Dendritic Cell Cancer Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Dendritic Cell Cancer Vaccine Sales by Region (2018-2023) & (Units)
Table 37. Asia Pacific Dendritic Cell Cancer Vaccine Sales by Region (2024-2029) & (Units)
Table 38. Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Dendritic Cell Cancer Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Dendritic Cell Cancer Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Dendritic Cell Cancer Vaccine Sales by Country (2018-2023) & (Units)
Table 42. Latin America Dendritic Cell Cancer Vaccine Sales by Country (2024-2029) & (Units)
Table 43. Latin America Dendritic Cell Cancer Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Dendritic Cell Cancer Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Dendritic Cell Cancer Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Dendritic Cell Cancer Vaccine Sales by Country (2018-2023) & (Units)
Table 47. Middle East & Africa Dendritic Cell Cancer Vaccine Sales by Country (2024-2029) & (Units)
Table 48. Middle East & Africa Dendritic Cell Cancer Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Dendritic Cell Cancer Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Dendritic Cell Cancer Vaccine Sales (Units) by Type (2018-2023)
Table 51. Global Dendritic Cell Cancer Vaccine Sales (Units) by Type (2024-2029)
Table 52. Global Dendritic Cell Cancer Vaccine Sales Market Share by Type (2018-2023)
Table 53. Global Dendritic Cell Cancer Vaccine Sales Market Share by Type (2024-2029)
Table 54. Global Dendritic Cell Cancer Vaccine Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Dendritic Cell Cancer Vaccine Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Type (2018-2023)
Table 57. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Type (2024-2029)
Table 58. Global Dendritic Cell Cancer Vaccine Price (USD/Unit) by Type (2018-2023)
Table 59. Global Dendritic Cell Cancer Vaccine Price (USD/Unit) by Type (2024-2029)
Table 60. Global Dendritic Cell Cancer Vaccine Sales (Units) by Application (2018-2023)
Table 61. Global Dendritic Cell Cancer Vaccine Sales (Units) by Application (2024-2029)
Table 62. Global Dendritic Cell Cancer Vaccine Sales Market Share by Application (2018-2023)
Table 63. Global Dendritic Cell Cancer Vaccine Sales Market Share by Application (2024-2029)
Table 64. Global Dendritic Cell Cancer Vaccine Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Dendritic Cell Cancer Vaccine Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Application (2018-2023)
Table 67. Global Dendritic Cell Cancer Vaccine Revenue Market Share by Application (2024-2029)
Table 68. Global Dendritic Cell Cancer Vaccine Price (USD/Unit) by Application (2018-2023)
Table 69. Global Dendritic Cell Cancer Vaccine Price (USD/Unit) by Application (2024-2029)
Table 70. Activarti Corporation Information
Table 71. Activarti Description and Business Overview
Table 72. Activarti Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 73. Activarti Dendritic Cell Cancer Vaccine Product
Table 74. Activarti Recent Developments/Updates
Table 75. Argos Therapeutics Corporation Information
Table 76. Argos Therapeutics Description and Business Overview
Table 77. Argos Therapeutics Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 78. Argos Therapeutics Dendritic Cell Cancer Vaccine Product
Table 79. Argos Therapeutics Recent Developments/Updates
Table 80. SOTIO (Acquired by PPF Group) Corporation Information
Table 81. SOTIO (Acquired by PPF Group) Description and Business Overview
Table 82. SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 83. SOTIO (Acquired by PPF Group) Dendritic Cell Cancer Vaccine Product
Table 84. SOTIO (Acquired by PPF Group) Recent Developments/Updates
Table 85. Bellicum Pharmaceuticals Corporation Information
Table 86. Bellicum Pharmaceuticals Description and Business Overview
Table 87. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 88. Bellicum Pharmaceuticals Dendritic Cell Cancer Vaccine Product
Table 89. Bellicum Pharmaceuticals Recent Developments/Updates
Table 90. JW CreaGene Corporation Information
Table 91. JW CreaGene Description and Business Overview
Table 92. JW CreaGene Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 93. JW CreaGene Dendritic Cell Cancer Vaccine Product
Table 94. JW CreaGene Recent Developments/Updates
Table 95. DanDrit Corporation Information
Table 96. DanDrit Description and Business Overview
Table 97. DanDrit Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 98. DanDrit Dendritic Cell Cancer Vaccine Product
Table 99. DanDrit Recent Developments/Updates
Table 100. DCPrime Corporation Information
Table 101. DCPrime Description and Business Overview
Table 102. DCPrime Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 103. DCPrime Dendritic Cell Cancer Vaccine Product
Table 104. DCPrime Recent Developments/Updates
Table 105. Elios Therapeutics Corporation Information
Table 106. Elios Therapeutics Description and Business Overview
Table 107. Elios Therapeutics Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 108. Elios Therapeutics Dendritic Cell Cancer Vaccine Product
Table 109. Elios Therapeutics Recent Developments/Updates
Table 110. ImmunoCellular Therapeutics Corporation Information
Table 111. ImmunoCellular Therapeutics Description and Business Overview
Table 112. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 113. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Product
Table 114. ImmunoCellular Therapeutics Recent Developments/Updates
Table 115. Kiromic Corporation Information
Table 116. Kiromic Description and Business Overview
Table 117. Kiromic Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 118. Kiromic Dendritic Cell Cancer Vaccine Product
Table 119. Kiromic Recent Developments/Updates
Table 120. Medigene Corporation Information
Table 121. Medigene Description and Business Overview
Table 122. Medigene Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 123. Medigene Dendritic Cell Cancer Vaccine Product
Table 124. Medigene Recent Developments/Updates
Table 125. Merck Corporation Information
Table 126. Merck Description and Business Overview
Table 127. Merck Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 128. Merck Dendritic Cell Cancer Vaccine Product
Table 129. Merck Recent Developments/Updates
Table 130. Northwest Biotherapeutics Corporation Information
Table 131. Northwest Biotherapeutics Description and Business Overview
Table 132. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 133. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Product
Table 134. Northwest Biotherapeutics Recent Developments/Updates
Table 135. Immutep Limited Corporation Information
Table 136. Immutep Limited Description and Business Overview
Table 137. Immutep Limited Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 138. Immutep Limited Dendritic Cell Cancer Vaccine Product
Table 139. Immutep Limited Recent Developments/Updates
Table 140. Dendreon Corporation Corporation Information
Table 141. Dendreon Corporation Description and Business Overview
Table 142. Dendreon Corporation Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 143. Dendreon Corporation Dendritic Cell Cancer Vaccine Product
Table 144. Dendreon Corporation Recent Developments/Updates
Table 145. Oncobiomed Corporation Information
Table 146. Oncobiomed Description and Business Overview
Table 147. Oncobiomed Dendritic Cell Cancer Vaccine Sales (Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 148. Oncobiomed Dendritic Cell Cancer Vaccine Product
Table 149. Oncobiomed Recent Developments/Updates
Table 150. Key Raw Materials Lists
Table 151. Raw Materials Key Suppliers Lists
Table 152. Dendritic Cell Cancer Vaccine Distributors List
Table 153. Dendritic Cell Cancer Vaccine Customers List
Table 154. Dendritic Cell Cancer Vaccine Market Trends
Table 155. Dendritic Cell Cancer Vaccine Market Drivers
Table 156. Dendritic Cell Cancer Vaccine Market Challenges
Table 157. Dendritic Cell Cancer Vaccine Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Dendritic Cell Cancer Vaccine
Figure 2. Global Dendritic Cell Cancer Vaccine Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Dendritic Cell Cancer Vaccine Market Share by Type in 2022 & 2029
Figure 4. CreaVax Product Picture
Figure 5. Sipuleucel-T (Provenge) Product Picture
Figure 6. Others Product Picture
Figure 7. Global Dendritic Cell Cancer Vaccine Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Dendritic Cell Cancer Vaccine Market Share by Application in 2022 & 2029
Figure 9. Pediatrics
Figure 10. Adults
Figure 11. Global Dendritic Cell Cancer Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 12. Global Dendritic Cell Cancer Vaccine Market Size (2018-2029) & (US$ Million)
Figure 13. Global Dendritic Cell Cancer Vaccine Sales (2018-2029) & (Units)
Figure 14. Global Dendritic Cell Cancer Vaccine Average Price (USD/Unit) & (2018-2029)
Figure 15. Dendritic Cell Cancer Vaccine Report Years Considered
Figure 16. Dendritic Cell Cancer Vaccine Sales Share by Manufacturers in 2022
Figure 17. Global Dendritic Cell Cancer Vaccine Revenue Share by Manufacturers in 2022
Figure 18. The Global 5 and 10 Largest Dendritic Cell Cancer Vaccine Players: Market Share by Revenue in 2022
Figure 19. Dendritic Cell Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 20. Global Dendritic Cell Cancer Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 21. North America Dendritic Cell Cancer Vaccine Sales Market Share by Country (2018-2029)
Figure 22. North America Dendritic Cell Cancer Vaccine Revenue Market Share by Country (2018-2029)
Figure 23. U.S. Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 24. Canada Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Europe Dendritic Cell Cancer Vaccine Sales Market Share by Country (2018-2029)
Figure 26. Europe Dendritic Cell Cancer Vaccine Revenue Market Share by Country (2018-2029)
Figure 27. Germany Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. France Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. U.K. Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Italy Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Russia Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Asia Pacific Dendritic Cell Cancer Vaccine Sales Market Share by Region (2018-2029)
Figure 33. Asia Pacific Dendritic Cell Cancer Vaccine Revenue Market Share by Region (2018-2029)
Figure 34. China Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Japan Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. South Korea Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. India Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Australia Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Taiwan Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Indonesia Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Thailand Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Malaysia Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Philippines Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Dendritic Cell Cancer Vaccine Sales Market Share by Country (2018-2029)
Figure 45. Latin America Dendritic Cell Cancer Vaccine Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Dendritic Cell Cancer Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Dendritic Cell Cancer Vaccine Sales Market Share by Country (2018-2029)
Figure 50. Middl
  • Global BCG Vaccine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96
    According to our LPI (LP Information) latest study, the global BCG Vaccine market size was valued at US$ 365.6 million in 2023. With growing demand in downstream market, the BCG Vaccine is forecast to a readjusted size of US$ 542.8 million by 2030 with a CAGR of 5.8% during review period. The research report highlights the growth potential of the global BCG Vaccine market. BCG Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing cost......
  • Global Peptide Cancer Vaccine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 115
    According to our LPI (LP Information) latest study, the global Peptide Cancer Vaccine market size was valued at US$ 535 million in 2023. With growing demand in downstream market, the Peptide Cancer Vaccine is forecast to a readjusted size of US$ 1978.2 million by 2030 with a CAGR of 20.5% during review period. The research report highlights the growth potential of the global Peptide Cancer Vaccine market. Peptide Cancer Vaccine are expected to show stable growth in the future market. How......
  • Global Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global Cancer Vaccine market: According to our latest research, the global Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Cancer Vaccine market was estimated at USD 7198.2 million, and it's anticipated to reach USD 33936.62 million in 2028, with a CAGR of 29.49% during the forecast years. A cancer vaccine is a type of immunotherapy that boost the body's natural defenses by stimulating the immune system to recognize and cur......
  • Global Lung Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 12-Dec-2023        Price: US 3380 Onwards        Pages: 102
    Market Overview of Global Lung Cancer Vaccines market: According to our latest research, the global Lung Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Lung Cancer Vaccines market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Lung Cancer Vaccines,A cancer vaccine for lung cance This report covers a research time span from 2018 to 2028, and ......
  • Global Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 07-Dec-2023        Price: US 3380 Onwards        Pages: 105
    Market Overview of Global Cancer Vaccines market: According to our latest research, the global Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Cancer Vaccines market was estimated at USD 5773.14 million, and it's anticipated to reach USD 15406.41 million in 2028, with a CAGR of 17.77% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Vacci......
  • Global Dendritic Cell Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 110
    Market Overview of Global Dendritic Cell Cancer Vaccine market: According to our latest research, the global Dendritic Cell Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Dendritic Cell Cancer Vaccine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Dendritic cells (DC) are one of the major antigen presenting cells found in lymphoid organs. The main fu......
  • Global BCG Vaccine Market Research Report 2023, Forecast to 2028
    Published: 14-Nov-2023        Price: US 2680 Onwards        Pages: 135
    BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......
  • Global BCG Vaccine Professional Survey Report 2023, Forecast to 2028
    Published: 14-Nov-2023        Price: US 3280 Onwards        Pages: 105
    BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......
  • Infectious Vaccine Collaboration and Licensing Deals 2016-2023
    Published: 01-Nov-2023        Price: US 3995 Onwards        Pages: 300
    Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious vaccine deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of infectious vaccine deals from 2016 to 2023. The report provides a detailed understanding and analysis of how and why companies enter infectious vaccine deals. These deals tend to be multicomponent, starting with......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs